交銀國際:予麗珠醫藥(1513.HK)及復星醫藥(2196.HK)“買入”評級
交銀國際發佈報告稱,繼續看好檢測試劑概念股短期走勢,如麗珠醫藥(1513.HK)及復星醫藥(2196.HK),兩者評級均為“買入”。
該行稱,麗珠醫藥的阿立哌唑微球獲國家藥監局批准展開臨牀試驗,其干擾素α-2b Fc融合蛋白也即將展開臨牀試驗。而復星醫藥正在研發的產品FCN-338片及FCN-159片均獲國家藥監局試驗註冊審評受理,其HLX56單抗獲中國台灣衞生福利部臨牀試驗批准。
該行還稱,京津冀及另外六省聯合展開醫用耗材採購競價,25款產品擬被選中,最高減幅達84.7%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.